Bayer forms cancer-drug partnership with Loxo
Alliance could see Loxo net up to $1.55bn in upfront and milestone payments
Tiny US biopharmaceutical firm Loxo Oncology will team up with German chemical giant Bayer to commercialise two therapies for patients with genetically defined cancers.